CRE Notice to FDA: TPSAC Violates FACA

See the attached memorandum which explains in detail the reasons why the Constitutents Subcommitee is in violation of FACA. Hopefully, FDA will address these issues  administratively so as not to necessiate other corrective actions.

CRE’s objective is to make FDA aware of  its non-compliance with FACA so it will not make the same mistakes when it establshes the menthol subcommittee.

See CRE  coverage in  FDA Week


1 comment. Leave a Reply

  1. Anonymous


    All those interested need to review the questions that TPSAC must answer on August 30. See

    The CTP seems to have forgotten to read FDA guidance documents as wll as basic toxicology textbooks.

Leave a Reply

Please Answer: *